Literature DB >> 28899866

Subacute endovascular recanalization of symptomatic cerebral artery occlusion: a propensity score-matched analysis.

Sang Hun Lee1,2, Dae Chul Suh2, Su Hee Cho3, Jae Jon Sheen2, Deok Hee Lee2, Jong S Kim4.   

Abstract

BACKGROUND: The interval between the onset of cerebral vessel occlusion and recanalization has been shown to be an independent predictor of poor outcomes. However, endovascular recanalization of symptomatic cerebral vessel occlusion in the subacute period has not been well documented. We investigated the safety and efficacy of subacute recanalization of occluded cerebral vessels in patients with ischemic stroke or transient ischemic attacks (TIAs).
METHODS: Between 2014 and 2015, 98 patients were admitted to the emergency room for ischemic stroke or TIA with a small infarct core, which was defined as modest early ischemic change on non-contrast CT or overt diffusion-perfusion mismatch. All patients underwent pre-transfemoral cerebral angiography and post-endovascular treatment. The patients were classified according to acute (onset-to-groin puncture time ≤6 hours) or subacute (onset-to-groin puncture time >6 hours) recanalization. Using propensity score analysis, recipients of acute and subacute recanalization underwent 1:1 matching.
RESULTS: Following 1:1 propensity score matching, 32 patients who underwent acute and 32 who underwent subacute intra-arterial thrombolysis were matched. There were no significant differences in National Institutes of Health Stroke Scale at discharge, modified Rankin scale (mRS), the proportion of patients with an mRS value of 0-2, mortality at discharge, intracerebral bleeding, postprocedural infarct extension, newly detected infarction, and hyperintense acute reperfusion marker on follow-up images between the acute and subacute recanalization groups.
CONCLUSIONS: In selected patients with clinically unstable cerebral artery occlusions, a diffusion-perfusion mismatch and small CT lesions, subacute and acute recanalization has comparable safety and efficacy rates. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  stroke; thrombectomy; thrombolysis

Mesh:

Year:  2017        PMID: 28899866     DOI: 10.1136/neurintsurg-2017-013219

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  5 in total

1.  Effect of electro-acupuncture therapy on limb spasm and excitability of motor neurons in stroke rats.

Authors:  Junxia Liu; Guigui Zhao; Yan Niu; Ting Gan; Zhenyu Yan; Yasu Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-06-25

2.  Endovascular recanalization for symptomatic intracranial internal carotid and middle cerebral artery occlusion lasting longer than 72 h: Experience in a single center.

Authors:  Guangwen Li; Peng Liu; Wentao Gong; Xianjun Zhang; Yong Zhang; Naidong Wang
Journal:  Brain Circ       Date:  2021-12-21

3.  Safety and efficacy of the SeparGate™ balloon-guiding catheter in neurointerventional surgery: Study protocol of a prospective multicenter single-arm clinical trial.

Authors:  Huan Liu; Tianxiao Li; Zhaoshuo Li; Liangfu Zhu; Yingkun He
Journal:  J Interv Med       Date:  2020-03-29

4.  Clinical Outcomes of Endovascular Treatment for Carotid Artery Dissection Without Intracranial Large Vessel Occlusion in Patients With Cerebral Ischemia Presentation.

Authors:  Joong-Goo Kim; Chul-Hoo Kang; Jay Chol Choi; Yunsun Song; Dae Chul Suh; Deok Hee Lee
Journal:  Front Neurol       Date:  2022-02-02       Impact factor: 4.003

Review 5.  CSF enhancement on post-contrast fluid-attenuated inversion recovery images; a systematic review.

Authors:  Whitney M Freeze; Merel van der Thiel; Jeroen de Bresser; Catharina J M Klijn; Ellis S van Etten; Jacobus F A Jansen; Louise van der Weerd; Heidi I L Jacobs; Walter H Backes; Susanne J van Veluw
Journal:  Neuroimage Clin       Date:  2020-10-02       Impact factor: 4.881

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.